Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Cancer care

Constipation treatment could lengthen cancer survival

Study findings support a role for the mu opioid receptor in cancer progression.

Dr Jonathan Moss, one of the lead researchers of the article

Courtesy of Jonathan Moss

One of the lead researchers, Jonathan Moss, from the University of Chicago, identified a benefit of laxation on survival of cancer patients

Recent data suggest that the mu opioid receptor (MOR), which is commonly the target of constipation treatments, could also be a target for anticancer therapy. 

US researchers explored this hypothesis by studying survival data for 229 advanced cancer patients involved in two placebo-controlled trials of the MOR antagonist methylnaltrexone (MNTX) for opioid-induced constipation. 

They found that patients who received MNTX survived significantly longer on average, at 76 days, compared with 56 days among those who received placebo. In patients who responded to MNTX with laxation, average survival was even longer at 118 days, while survival in non-responders was similar to placebo at 55 days. 

Reporting in the Annals of Oncology (online, 29 August 2016)[1], the researchers say the findings support a role for the MOR in cancer progression and prospective studies of MNTX are warranted to confirm the clinical relevance of their results.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201687

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Dr Jonathan Moss, one of the lead researchers of the article "Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer”

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.